Evidence analysisNovember 3, 2026Health & Science
Human medicines European public assessment report (EPAR): Bildyos, denosumab, Date of authorisation: 17/09/2025, Revision: 5, Status: Authorised

FreedomWitness Evidence Engine: This is an AI-assisted original analysis built from the linked source and available public source context. It separates evidence from interpretation and may challenge conventional framing only where the evidence supports it. It is not a copied article.
What is established
Bildyos is a biosimilar medicine containing the active substance denosumab, authorized for use in the European Union as of September 17, 2025. It is approved to treat osteoporosis in postmenopausal women and in men with increased risk of fractures, as well as bone loss in patients receiving corticosteroid treatment or prostate cancer therapy that increases fracture risk. Bildyos is administered as a subcutaneous injection every six months. It works by targeting RANKL, a protein that activates osteoclasts, the cells responsible for bone resorption, thereby reducing bone loss and fracture risk.
The European Medicines Agency (EMA) reviewed laboratory and clinical data that showed Bildyos’s active substance is highly similar to that in the reference medicine Prolia in terms of structure, purity, and biological activity. A clinical study involving 514 postmenopausal women with osteoporosis demonstrated comparable efficacy in bone mineral density increase between Bildyos and Prolia after one year of treatment. Additionally, safety profiles were found to be similar, with common side effects being musculoskeletal pain and rare but serious effects including osteonecrosis of the jaw and unusual femoral fractures.
What the source claims
- Biosimilarity: Bildyos matches Prolia closely in molecular composition and pharmacokinetics.
- Efficacy: Studies confirm Bildyos performs equivalently to Prolia in improving bone mineral density in osteoporosis patients.
- Safety: The side effect profile of Bildyos is comparable to that of Prolia, with some risks such as hypocalcemia and osteonecrosis of the jaw highlighted.
- Usage instructions: Calcium and vitamin D supplementation are recommended alongside treatment; healthcare professionals should monitor patients accordingly.
- Regulatory decision: EMA’s approval is based on biosimilarity criteria and clinical evidence indicating that Bildyos’s benefits outweigh the risks, allowing marketing authorization across the EU.
- Risk management: Patients receive information cards about osteonecrosis of the jaw, and continuous monitoring of reported side effects is emphasized.
What may be missing from the usual framing
The official assessment by EMA focuses on biochemical similarity and short-term clinical equivalence, relying substantially on data extrapolated from the reference medicine Prolia’s extensive trials. There is limited information provided on the long-term effects or rare adverse events specifically associated with Bildyos in real-world settings beyond the one-year osteoporosis study. The patient experience with biosimilars like Bildyos can also be affected by factors such as injection delivery systems or immunogenicity that may not be fully captured in pre-approval studies. The role of healthcare system cost considerations, biosimilar uptake barriers, and patient adherence in treatment outcomes is not discussed in the source.
Competing evidence or uncertainty
The EMA document reviewed does not present competing data but relies on the established clinical trial data of Prolia and a confirmatory biosimilarity study of Bildyos. Evidence on equivalence pertains primarily to postmenopausal osteoporosis, while data for other approved indications like corticosteroid-induced bone loss or fracture risk in prostate cancer patients may be limited or extrapolated. Observational or post-market studies may eventually provide insights into safety signals that clinical trials cannot detect due to sample size or duration constraints.
Furthermore, the biosimilar approval paradigm inherently introduces some uncertainty due to the lack of full independent clinical trials for every indication. While EMA’s regulatory framework is robust, the equivalence in clinical effectiveness and side effect profiles in diverse patient populations over extended periods remains an area for continued monitoring.
Why it matters
Osteoporosis is a significant cause of morbidity in aging populations, especially among postmenopausal women and patients undergoing therapies that weaken bones. Medicines like Bildyos aim to reduce fracture risk and improve quality of life by preserving bone strength. The availability of biosimilars such as Bildyos can potentially lower treatment costs and increase access to effective therapies, which is crucial given the high economic burden of osteoporotic fractures.
By ensuring biosimilarity, regulators like EMA seek to maintain patient safety and therapeutic standards while encouraging market competition. Understanding the nuances of biosimilar approval and the reliance on reference medicine data is essential for clinicians, patients, and policymakers to make informed decisions about treatment options and post-marketing surveillance.
What to verify next
- Long-term safety data on Bildyos, especially regarding rare but serious side effects like osteonecrosis of the jaw and atypical femoral fractures.
- Real-world effectiveness and patient adherence compared to the reference medicine Prolia.
- Data specific to non-osteoporotic indications approved for Bildyos, including effects in men receiving prostate cancer treatments and patients on long-term corticosteroids.
- Information on immunogenicity and potential differences in immune response due to biosimilar manufacturing processes.
- Economic impact and access improvements resulting from biosimilar introduction in EU healthcare settings.
Readers should consult the original EMA assessment and accompanying product information for comprehensive details and updates as further evidence emerges.
Source & verification
Primary source: What's new · November 3, 2026
FreedomWitness links to the original source so readers can inspect the underlying material and judge the context for themselves.
Continue reading

EudraGMDP database
What is established The EudraGMDP database is an established European Union (EU) information system managed by the European Medicines Agency (EMA). It serves as…

Antimicrobial resistance in the EU/EEA (EARS-Net) – Annual Epidemiological Report for 2025
Evidence Dossier: Antimicrobial Resistance Trends in the EU/EEA 2025 Antimicrobial Resistance Trends in the EU/EEA: Evidence from the 2025 EARS-Net Report What is established…

Rapid risk assessment – Carbapenem-resistant Enterobacterales, fourth update
Evidence Dossier: Carbapenem-resistant Enterobacterales (CRE) in the EU/EEA – Latest Scientific Assessment What is established Carbapenem-resistant Enterobacterales (CRE), which include bacteria such as Klebsiella…